Testosterone is a potent inhibitor of L-type Ca(2+) channels.
about
Testosterone for the aging male; current evidence and recommended practiceTestosterone and the cardiovascular system: a comprehensive review of the basic science literatureTestosterone and the cardiovascular system: a comprehensive review of the clinical literatureTestosterone replacement therapy: current trends and future directionsGlucose-6-phosphate dehydrogenase and NADPH redox regulates cardiac myocyte L-type calcium channel activity and myocardial contractile functionNew facets of androgen replacement therapy during childhood and adolescence.Androgens induce nongenomic stimulation of colonic contractile activity through induction of calcium sensitization and phosphorylation of LC20 and CPI-17.Regulation of the sperm calcium channel CatSper by endogenous steroids and plant triterpenoids.Do androgens play a beneficial role in the regulation of vascular tone? Nongenomic vascular effects of testosterone metabolites.Testosterone and cholesterol vasodilation of rat aorta involves L-type calcium channel inhibition.Effect modification of obesity on associations between endogenous steroid sex hormones and arterial calcification in women at midlife.Anabolic androgenic steroids and intracellular calcium signaling: a mini review on mechanisms and physiological implications.Regional differences in the vasorelaxing effects of testosterone and its 5-reduced metabolites in the canine vasculature.Testosterone-induced relaxation of coronary arteries: activation of BKCa channels via the cGMP-dependent protein kinase.Sex hormones and the QT interval: a review.Androgens, insulin resistance and vascular disease in men.Weapons of penile smooth muscle destruction: androgen deficiency promotes accumulation of adipocytes in the corpus cavernosum.Evidence for the participation of calcium in non-genomic relaxations induced by androgenic steroids in rat vas deferens.Basic Science Evidence for the Link Between Erectile Dysfunction and Cardiometabolic Dysfunction.Testosterone and cardiovascular disease in men.NF-kB overexpression and decreased immunoexpression of AR in the muscular layer is related to structural damages and apoptosis in cimetidine-treated rat vas deferensThe relationship between hypogonadism and erectile dysfunction.Characterization of the vasodilatory action of testosterone in the human pulmonary circulation.Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response.Testosterone therapy: treatment of metabolic disturbances in heart failure.Hormonal effects on blood vessels.The effect of testosterone on cardiovascular disease: a critical review of the literature.Molecular effects of supraphysiological doses of doping agents on health.Association of admission testosterone level with ST-segment resolution in male patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective.Recent Progress in Vascular Aging: Mechanisms and Its Role in Age-related Diseases.Testosterone relaxes rabbit seminal vesicle by calcium channel inhibition.Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer.Endogenous testosterone increases L-type Ca2+ channel expression in porcine coronary smooth muscle.Testosterone acts as an efficacious vasodilator in isolated human pulmonary arteries and veins: evidence for a biphasic effect at physiological and supra-physiological concentrations.Larger dispersion of INa in female dog ventricle as a mechanism for gender-specific incidence of cardiac arrhythmias.Androgens induce relaxation of contractile activity in pregnant human myometrium at term: a nongenomic action on L-type calcium channels.Testosterone-induced relaxation involves L-type and store-operated Ca2+ channels blockade, and PGE 2 in guinea pig airway smooth muscle.Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial.Inverse association between total testosterone concentrations, incident hypertension and blood pressure.
P2860
Q24647679-BE3E6967-81DD-4CE4-9A39-1AE6115DC79DQ26824556-57411A1A-AEA7-4D80-A173-32C143CAD287Q27000507-95664596-9330-40A7-840C-F2792AE95D83Q28275913-C13C6D4C-8B1F-4BC2-90AE-1340EBD9A640Q28580561-F011BEF8-CB1C-4ECE-B9D0-608E1C63739BQ30437366-A8E09536-CA42-4219-93D8-9EBC2E2C7784Q33637557-A0690326-7C21-4D60-BA0A-A03F4954AF03Q33782521-8D8A2EC4-B57A-4709-AB20-AAD60577468AQ33840760-06573DC7-F92A-4674-AEC0-9AEBE125632CQ34342113-0F3DC63B-FF5C-499F-848A-035F74CAA56AQ35234657-145427E1-A2E7-4328-BA87-60430B6EDC2BQ35559000-04FCCB6A-B423-4ED8-B274-9E77D5FE321DQ35853947-1BC1CEFC-5779-4DA3-AB80-6407627B8CC3Q35906456-DA049581-0269-4F7F-9663-455C0E67352AQ36198040-1C9CAE4A-F6AD-4BCD-940C-B4EED6B55CF1Q36238752-40925054-D51C-4F62-A7A1-4A3FAF3C2095Q36359537-411C43E1-E9A5-476A-801F-0067B89C8745Q36510049-4DC6E68A-1E7B-4831-8D1C-796B5D6FEE77Q36861695-8CE654A2-FCB9-4110-AAF0-F8B84293961DQ37037827-4FAF7186-2EF7-404A-8B40-E342B666A208Q37056676-1E3E5329-67E8-4AC7-979E-ED323E0182D3Q37096549-BDAA11DA-3FDC-4756-B25F-D441D48DD2CFQ37145656-0EBFCDD7-189B-45CC-9E51-EA6F7F5BF537Q37671277-7A90F910-E869-46AA-8853-D1FEE7623A2EQ37811621-0C81A92B-DAFA-4798-B5D5-F7F5A8B522B7Q37980611-FA80FF65-C4ED-4177-8854-68E00E3D8D27Q38190531-2C9461AA-EEA3-4C0C-B6F7-047F1C5F2D40Q38383101-560063E8-DE0D-4724-9580-AAC56877D4DAQ38645404-7DED550A-1A3C-4D2F-A969-CBD896C38E18Q38852165-2F34946B-FCE9-4650-92CD-58A2496B5A0EQ41108769-347D3025-D2EB-4199-BD60-45234A69AF4EQ41957926-27CD2E92-EAA3-4573-B938-FC95E62BD854Q42139750-FB13A6EC-DA69-40A2-B9FB-5E83957EE87EQ44970299-C321C365-A1D5-43B6-AF70-0DDA8589C8CCQ45964748-8E5C22B7-AADD-4693-9A11-0B8A7DF93748Q46355471-E98C0D3E-35EA-4077-980F-A9600800DDAEQ46367908-923DD60D-A2C3-4408-A202-D572E96FF75AQ46522377-7B174352-7EA2-4C3C-ABB0-0BE2848C32B2Q46644252-C7588D4F-43B6-4150-B944-616A58F1117FQ46710898-AEE7995A-E5A2-4D5E-9B00-57A69F2F13FB
P2860
Testosterone is a potent inhibitor of L-type Ca(2+) channels.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Testosterone is a potent inhibitor of L-type Ca(2+) channels.
@en
Testosterone is a potent inhibitor of L-type Ca(2+) channels.
@en-gb
type
label
Testosterone is a potent inhibitor of L-type Ca(2+) channels.
@en
Testosterone is a potent inhibitor of L-type Ca(2+) channels.
@en-gb
prefLabel
Testosterone is a potent inhibitor of L-type Ca(2+) channels.
@en
Testosterone is a potent inhibitor of L-type Ca(2+) channels.
@en-gb
P2093
P1476
Testosterone is a potent inhibitor of L-type Ca(2+) channels.
@en
P2093
Kevin S Channer
Richard D Jones
T Hugh Jones
P304
P356
10.1016/J.BBRC.2004.04.054
P577
2004-05-01T00:00:00Z